Viking Therapeutics (VKTX) stock price forecast: what to expect?

2:35 pm ET, 31 May 2018

Viking Therapeutics (VKTX) stock shot up over 100%, despite the fact that ValueEngine downgraded the company from  Strong Buy to Buy.

The stock moved up in response to Madrigal Pharmaceuticals' announcement of successful 36-week results from a Phase 2 study of NonAlcoholic SteatoHepatitis (NASH) candidate MGL-3196, a thyroid hormone receptor-beta agonist.  Viking's NASH candidate, Phase 2-stage VK2809, has the same mechanism of action. 

What can you expect now--and what's the VKTX stock price forecast?  

We looked at the technical analysis for Viking.  The short-term sentiment is weak, while mid- and long-term the stock looks strong.  

Based on Finstead research, VKTX stock upside is negative (you can also search for 'VKTX upside' on Finstead.com to get the latest results).

Over the last year, VKTX returned +623.47%.  This return is higher than Biotechnology sector (47.47%), Healthcare industry (38.13%), S&P 500 (12.95%)  returns.

Viking Therapeutics is a clinical-stage biopharmaceutical company, focused on the development of therapies for metabolic and endocrine disorders. Its lead clinical program is VK5211, which is in phase II clinical trials for acute rehabilitation following hip fracture surgery. 

The company also develops VK2809 for the treatment of hypercholesterolemia and fatty liver disease, which is looking quite promising, based on today's news.

Disclaimer: The news article above expresses the author’s opinion about the topic of the article. We strongly advise you not to base your investment decisions just on this article alone. If you’d like to become a writer for AskFinny Bites, please send us an email at hi@askfinny.com.

Viking Therapeutics, Inc. (VKTX) Buy or Sell Stock Guide

Updated at: 7:42 pm ET, 13 Nov 2019

Are you looking for the analysis of Viking Therapeutics, Inc. (VKTX) stock? Are you wondering what the bulls and the bears say about it?

If so, you came to the right place. In this stock guide, we will share with you 3 reasons to buy and 3 reasons to sell VKTX stock. You’ll get a perspective on what the bulls and the bears say about it.

The analysis below may be also helpful to you if you have any of the following questions about VKTX stock:

  • Is VKTX a buy or a sell?
  • Should I sell or hold VKTX stock today?
  • Is VKTX a good buy / investment?
  • What are VKTX analyst opinions, recommendations and ratings?

Let’s start with the bull case. Here are the reasons to buy VKTX stock:

1. VKTX Price/Book ratio is 1.68, and it’s low compared to its industry peers’ P/B ratios. See VKTX forward Price/Book ratio chart.

2. VKTX average analyst rating is Strong Buy. See VKTX analyst rating chart.

3. VKTX average analyst price target ($23.73) is above its current price ($8.40). See VKTX price target chart.

Now that you understand the bull case, let’s look at the reasons to sell VKTX stock (i.e., the bear case):

1. VKTX stock price ($8.40) is close to the 52-week high ($8.64). Perhaps now is a good time to sell? See VKTX price chart.

2. VKTX short share of float is 32.11%. The stock is much more frequently shorted than the average industry, sector or S&P 500 stock. See VKTX short share of float chart.

3. VKTX short interest (days to cover the shorts) ratio is 13.6. The stock garners more short interest than the average industry, sector or S&P 500 stock. See VKTX short interest ratio chart.

Now let's look at the key statistics for VKTX:

Metrics VKTX
Price $7.62
Average Price Target / Upside $23.70 / 211.23%
Average Analyst Rating Buy
Industry Biotechnology
Sector Healthcare
Number of Employees 18
Market Cap $528.97M
Forward P/E Ratio -11.44
Price/Book Ratio N/A
PEG -0.47
Revenue (TTM) N/A
YoY Quarterly Revenue Growth N/A
Profit Margin 0.00%

What are your thoughts on VKTX?

If you liked this analysis, check out Buy or Sell Stock Guides for other stocks.

Disclaimer: The news article above expresses the author’s opinion about the topic of the article. We strongly advise you not to base your investment decisions just on this article alone. If you’d like to become a writer for AskFinny Bites, please send us an email at hi@askfinny.com.

Use AskFinny to ask any finance or investment question. Big or small. Personal or general.
Follow Us